The preclinical data obtained about the safety and efficacy of MV in MBs and AT/RTs supported the opening of a multi-center, Phase I study (NCT02962167) to determine the safety and preliminary efficacy of attenuated MV-NIS administered directly into the tumor bed (for locally recurrent MB or AT/RTs patients) or into the subarachnoid space (for disseminated recurrent MBs or AT/RTs patients) [66]. This evidence concerns the gene SLC5A5 and Mobius syndrome.